Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Introduction Although effective hepatitis B virus
2021-10-14

Introduction Although effective hepatitis B virus (HBV) vaccines are in use worldwide, HBV-related liver diseases are still a major public health concern, causing considerable morbidity and mortality. Approximately 257 million people are currently suffering from chronic hepatitis B and 887,000 de
-
br Introduction Soluble guanylyl cyclase GC maintains vascul
2021-10-14

Introduction Soluble guanylyl cyclase (GC-1) maintains vascular function through the NO/GC-1/cGMP pathway [1,2] by catalyzing the conversion of GTP into cGMP (Fig. 1). The GC-1 heme prosthetic group binds NO with picomolar affinity, resulting in a 100- to 200-fold increase in catalytic activity.
-
br Materials and methods br Results As
2021-10-14

Materials and methods Results As expected, due to matching by age, the mean ages were similar for the two groups of children when stratified by ASD status; children with an ASD had a mean age of 67.0 months, while the mean age for children in the TD control group was 68.0 months. Nearly all of
-
Glutathione in reduced form GSH the tripeptide glutamyl cyst
2021-10-14

Glutathione in reduced form (GSH, the tripeptide, γ-glutamyl cysteinyl glycine) is a non-enzymatic low-molecular-weight antioxidant necessary for the maintenance of a cellular redox state (Noctor et al., 2012). At the stage of the transition from germination to seedling growth the process of cell di
-
br Medium and long chain fatty
2021-10-14

Medium- and long-chain fatty cam kinase ii receptors Clinical studies of ω3 fatty acids Clinical studies have established that dietary intake of ω3 fatty acids should be around 4g/day for treating very high triglyceride levels (≥5.7mmol/L) [36]. Low-dose supplementation with EPA + DHA (400mg/
-
Apart from the different assays used
2021-10-14

Apart from the different assays used, biased agonism could also explain the inconsistent pharmacology of GPR55. Indeed, one study compared the effect of LPIs and Virodhamine in HEK293 wnt inhibitor stably transfected with human GPR55. They found that the effect of both ligands on intracellular Ca2+
-
br Acknowledgments This work was supported by
2021-10-14

Acknowledgments This work was supported by the National Institutes of Health (R01 A1084898) to M.V. Williams and M.E. Ariza. Introduction Female pattern hair loss (FPHL) has emerged as the preferred term for androgenetic alopecia (AGA) in women due to the uncertain relationship between andro
-
In conclusion we have designed
2021-10-14

In conclusion, we have designed and characterized a novel series of EAAT-blockers, exemplified by (-[4-(2-bromo-4,5-difluorophenoxy)phenyl]--asparagine)—a potent, selective, competitive non-substrate inhibitor of EAAT-2. As one of the most potent and selective EAAT-2 inhibitors identified to date,
-
In the present study we set out
2021-10-14

In the present study we set out to discover new non-steroidal SEGRA and to analyse their mechanism of function. Towards this goal we initiated a virtual screening (VS) approach, utilizing structure-based pharmacophore modeling, in silico docking and molecular dynamics (MD) simulations. Our pharmacop
-
Introduction Parkinson s Disease PD is a neurodegenerative
2021-10-14

Introduction Parkinson's Disease (PD) is a neurodegenerative disease affecting approximately 5–6 million individuals worldwide [1]. This number is expected to escalate to ∼10 million by the year 2030 as the world's population rapidly ages [2]. In the United States, more than 1 million individuals h
-
Using data from a large population
2021-10-14

Using data from a large population-based cohort study in Finnish males and females, Suchankova et al. [97] looked at a subset of the aforementioned SNPs, namely one SNP on GHSR (rs2948694) and two SNPs on GHRL (rs4684677 and rs696217), in relation to alcohol use disorders identification test (AUDIT)
-
The identity of the K transport pathway activated
2021-10-14

The identity of the K+ transport pathway activated by NEM remains unclear. The pathway does not require the presence of Gardos channel KCNN4 or K–Cl cotransporters KCC3 and KCC1, but like these pathways is sensitive to the presence of hemoglobin S or other sickling hemoglobins. Although partially se
-
The patterns of Fig Fig emerge
2021-10-14

The patterns of Fig. 1, Fig. 2 emerge at the multicellular level; their dynamics can only be understood by integrating different magnitudes and feedback loops in networks incorporating the coupling between biochemical and bioelectrical signals (see Fig. 6, Fig. 8). Interestingly, this might also be
-
The NGS of six Southern Brazil
2021-10-13

The NGS of six Southern Brazil patients revealed three different variants: c.472C > T (p.Arg158Trp); c.958G>A (p.Gly320Arg) and c.986T>C (p.Leu329Pro) (Table 2). The amino acids involved in these substitutions were evolutionarily conserved in different species (Fig. 1B). The amino GW 6471 synthesis
-
Structurally HMTs can be broadly categorized into three func
2021-10-13

Structurally, HMTs can be broadly categorized into three functional enzymatic families, the SET (Suppressor of variegation, Enhancer of zeste, Trithorax)-domain- containing methyltransferases, the non-SET DOT1-like (DOT1L) lysine methyltransferases, the PRDM family, containing a PR (PRDI-BF1-RIZ1 ho
16629 records 608/1109 page Previous Next First page 上5页 606607608609610 下5页 Last page